Niki BioSolutions, Inc. is a Princeton, New Jersey-based biotechnology company focused on developing molecular diagnostic tools for neurological and other diseases. The company was formed in July 2026 through the combination of Aptorum Group Limited and DiamiR Biosciences Corp., with DiamiR continuing as a wholly owned subsidiary. Aptorum was subsequently domesticated in Delaware and renamed Niki BioSolutions.
The company’s principal diagnostic business develops minimally invasive, blood-based tests intended to detect and monitor mild cognitive impairment, Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions. Its research also has potential applications in neurodevelopmental disorders and cancer. The tests are designed to support disease screening, patient classification, diagnosis, and the monitoring of disease progression or responses to treatment.
Niki’s technology is based on measuring microRNAs found in blood plasma. MicroRNAs are small regulatory molecules associated with biological activity in particular organs, tissues, and cell types. Because certain brain-enriched microRNAs can enter the bloodstream, the company studies patterns in their concentration as possible indicators of neurological changes that may occur before clear symptoms emerge. Its CogniMIR diagnostic platform is being developed primarily for assessing cognitive impairment and Alzheimer’s-related neurodegeneration.
The company is working toward laboratory-developed diagnostic tests while also using its biomarker platform in research collaborations with pharmaceutical and biotechnology companies. These services may help drug developers identify suitable clinical-trial participants, separate patients into relevant groups, and evaluate whether experimental treatments are producing measurable biological effects. Niki therefore operates at the intersection of molecular diagnostics, neurological research, clinical testing, and therapeutic development.